Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years
Novartis AG (NYSE:NVS) released new data Wednesday from the ALITHIOS open-label extension study. Data show first-line ...
Novartis AG: Hold Rating Justified Amid Kisqali’s Market Potential and FDA Approval
Analyst Eric Le Berrigaud from Stifel Nicolaus maintained a Hold rating on Novartis AG (NOVN – Research Report) and keeping the price ...
Novartis Breast Cancer Drug Helped Delay Return of Disease
Novartis AG’s breast cancer drug helped prevent the disease coming back a year after treatment had ended, in new data that ...
C&EN1d
Novartis invests in 2 US radiopharmaceutical facilities
Novartis is making two investments in new radiopharmaceutical manufacturing sites in the US. The Swiss pharmaceutical giant will open a third US radioligand plant in Carlsbad, California, to serve the ...
Business Insider3d
Maintaining Hold on Novartis: Kisqali’s Approval Meets Expectations Amid Patent Risks
In a report released yesterday, Graham Parry from Bank of America Securities maintained a Hold rating on Novartis AG (NOVN – Research Report), with a price target of CHF110.00. Graham Parry has ...
Pharmabiz1d
New Novartis data in relapsing MS reinforce benefits of Kesimpta for first-line and switch patients
New Novartis data in relapsing MS reinforce benefits of Kesimpta for first-line and switch patients: Basel Friday, September 20, 2024, 12:00 Hrs [IST] Novartis announced new data ...
BioWorld3d
Novartis synthesizes fast-acting intravenous agents for malaria
The increasing resistance to intravenous artemisinin therapy for malaria highlights the urgent need for new treatments that offer better patient compliance and a single-dose cure to address this ...
STAT3d
FDA awards Novartis expanded approval for breast cancer therapy
The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...
Novartis Pharma AG: FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhi ...
Novartis Breast Cancer Drug Found To Cut Disease Recurrence
Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease.
FiercePharma3d
Novartis heaps pressure on Lilly with broad FDA approval for Kisqali in early breast cancer
An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early ...
Goldman Sachs Remains a Hold on Novartis AG (NOVN)
Goldman Sachs analyst James Quigley maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of ...